These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15175521)

  • 1. Community tobacco control leaders' perceptions of harm reduction.
    Joseph AM; Hennrikus D; Thoele MJ; Krueger R; Hatsukami D
    Tob Control; 2004 Jun; 13(2):108-13. PubMed ID: 15175521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tobacco harm reduction: what do the experts think?
    Martin EG; Warner KE; Lantz PM
    Tob Control; 2004 Jun; 13(2):123-8. PubMed ID: 15175526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harm reduction policies for tobacco users.
    Gartner C; Hall W
    Int J Drug Policy; 2010 Mar; 21(2):129-30. PubMed ID: 19944582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction.
    Kozlowski LT; Abrams DB
    BMC Public Health; 2016 May; 16():432. PubMed ID: 27221096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smokers' beliefs about the tobacco control potential of "a gene for smoking": a focus group study.
    Waters EA; Ball L; Carter K; Gehlert S
    BMC Public Health; 2014 Nov; 14():1218. PubMed ID: 25424390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Support for a tobacco endgame and increased regulation of the tobacco industry among New Zealand smokers: results from a National Survey.
    Edwards R; Wilson N; Peace J; Weerasekera D; Thomson GW; Gifford H
    Tob Control; 2013 May; 22(e1):e86-93. PubMed ID: 22535362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health.
    Bates C; Fagerström K; Jarvis MJ; Kunze M; McNeill A; Ramström L
    Tob Control; 2003 Dec; 12(4):360-7. PubMed ID: 14660767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
    Kozlowski LT
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Australian urban Indigenous smokers' perspectives on nicotine products and tobacco harm reduction.
    Yuke K; Ford P; Foley W; Mutch A; Fitzgerald L; Gartner C
    Drug Alcohol Rev; 2018 Jan; 37(1):87-96. PubMed ID: 28493405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The US tobacco control community's view of the future of tobacco harm reduction.
    Warner KE; Martin EG
    Tob Control; 2003 Dec; 12(4):383-90. PubMed ID: 14660773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harm reduction in U.S. tobacco control: Constructions in textual news media.
    Eversman MH
    Int J Drug Policy; 2015 Jun; 26(6):575-82. PubMed ID: 25727451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions to reduce harm from continued tobacco use.
    Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005231. PubMed ID: 17636791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harm reduction and the medicalisation of tobacco use.
    Rooke C
    Sociol Health Illn; 2013 Mar; 35(3):361-76. PubMed ID: 22670865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between tobacco industry denormalization beliefs, tobacco control community discontent and smokers' level of nicotine dependence.
    Kushnir V; Selby P; Cunningham JA
    Addict Behav; 2013 Jul; 38(7):2273-8. PubMed ID: 23583832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Smoking therapies: is harm reduction a viable alternative to smoking cessation?
    Zellweger JP
    Drugs; 2001; 61(8):1041-4. PubMed ID: 11465867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from the history of tobacco harm reduction: The National Cancer Institute's Smoking and Health Program and the "less hazardous cigarette".
    Parascandola M
    Nicotine Tob Res; 2005 Oct; 7(5):779-89. PubMed ID: 16191749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Australian mental health care practitioners' practices and attitudes for encouraging smoking cessation and tobacco harm reduction in smokers with severe mental illness.
    Sharma R; Meurk C; Bell S; Ford P; Gartner C
    Int J Ment Health Nurs; 2018 Feb; 27(1):247-257. PubMed ID: 28160384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory issues concerning the development and circulation of nicotine-containing products: a qualitative study.
    Rooke C; McNeill A; Arnott D
    Nicotine Tob Res; 2013 Jun; 15(6):1052-9. PubMed ID: 23128517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Origins of tobacco harm reduction in the UK: the 'Product Modification Programme' (1972-1991).
    Elias J; Ling PM
    Tob Control; 2018 Jul; 27(e1):e12-e18. PubMed ID: 29330172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobacco harm reduction: a call to address the ethical dilemmas.
    Fox BJ; Cohen JE
    Nicotine Tob Res; 2002; 4 Suppl 2():S81-7. PubMed ID: 12573170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.